Koshyk, OlenaRyspayeva, DinaraLyashenko, AndreyDosenko, Irina2024-12-262024-12-262020-01Ryspayeva D, Lyashenko A, Dosenko I, Kostryba O, Koshyk O, Krotevych M, Smolanka I. Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer. J BUON. 2020 Jan-Feb;25(1):168-175. PMID: 32277628.PMID: 32277628.https://ir.kmu.edu.ua/handle/123456789/693Purpose: To identify predictive factors connected with pathologic response in patients with breast cancer (BC) having received neoadjuvant chemotherapy (NACT). Methods: 49 patients with BC were investigated before and after treatment in this prospective research. Different chemotherapy regimes were administered. The Miller-Payne scoring system was used to assess the tumour response. The nuclear proliferation markers Ki67 and the expression of topoisomerase IIα (Topo IIα) were evaluated. Results: Six patients (12.2 %) achieved pathological complete response (pCR). Noticeable decrease of tumor cellularity was detected in all BC subtypes and pCR in the triple-negative BC (TNBC) group (p=0.007) was observed. Poorly differentiated tumors could be considered as predictive factors of pCR (p=0.07). Ki67 appeared to be a predictive marker of achieving pCR (p<0.001) with a threshold of 28% (AUC=0.89, 95% CI 0.75-0.96). The additional factor of reaching pCR was operable BC (p=0.04). The expression level of Topo IIα (p=0.50) and using different regimens of NACT (p=0.97) did not influence pCR achievement. Conclusion: To sum it up, poorly differentiated carcinomas with high cellularity in the primary tumor, TNBC, Ki 67 with a threshold above 28% and operable BC can be considered as early predictors of reaching pCR.en-USbreast cancerKi 67neoadjuvant chemotherapypathologic responseArticle